Safety and immunogenicity of nonadjuvanted and MF59-adjuvanted influenza A/H9N2 vaccine preparations. - Wikidata - wikimedia - TriplyDB

Safety and immunogenicity of nonadjuvanted and MF59-adjuvanted influenza A/H9N2 vaccine preparations.

Safety and immunogenicity of nonadjuvanted and MF59-adjuvanted influenza A/H9N2 vaccine preparations.

http://www.wikidata.org/entity/Q30357294

about

Immune mechanisms of protection: can adjuvants rise to the challenge?Near-infrared laser adjuvant for influenza vaccine A cell culture-derived MF59-adjuvanted pandemic A/H7N9 vaccine is immunogenic in adults.African green monkeys recapitulate the clinical experience with replication of live attenuated pandemic influenza virus vaccine candidates.Phase I/II randomized double-blind study of the safety and immunogenicity of a nonadjuvanted vero cell culture-derived whole-virus H9N2 influenza vaccine in healthy adults.Safety and immunogenicity of an inactivated influenza A/H5N1 vaccine given with or without aluminum hydroxide to healthy adults: results of a phase I-II randomized clinical trial.MF59-adjuvanted H5N1 vaccine induces immunologic memory and heterotypic antibody responses in non-elderly and elderly adults A live attenuated H9N2 influenza vaccine is well tolerated and immunogenic in healthy adults.Progress with human H5N1 vaccines: a perspective from industry.Current status and progress of prepandemic and pandemic influenza vaccine development.Safety and immunogenicity of Sinovac's prototype pandemic influenza H5N1 vaccines: a review on clinical trials.Characterization of a whole, inactivated influenza (H5N1) vaccine.Protective immunity against H5N1 influenza virus by a single dose vaccination with virus-like particles Impact of prior seasonal influenza vaccination and infection on pandemic A (H1N1) influenza virus replication in ferrets Nanotechnology and HIV: potential applications for treatment and prevention.MF59™ as a vaccine adjuvant: a review of safety and immunogenicity.Contemporary seasonal influenza A (H1N1) virus infection primes for a more robust response to split inactivated pandemic influenza A (H1N1) Virus vaccination in ferrets Evaluation of age-related differences in the immunogenicity of a G9 H9N2 influenza vaccine Aflunov®: a vaccine tailored for pre-pandemic and pandemic approaches against influenza.Evaluations for in vitro correlates of immunogenicity of inactivated influenza a H5, H7 and H9 vaccines in humans.Immunobiology of influenza vaccines A predictive model of the economic effects of an influenza vaccine adjuvant for the older adult (age 65 and over) population.A heterologous MF59-adjuvanted H5N1 prepandemic influenza booster vaccine induces a robust, cross-reactive immune response in adults and the elderly.Safety and immunogenicity of inactivated, Vero cell culture-derived whole virus influenza A/H5N1 vaccine given alone or with aluminum hydroxide adjuvant in healthy adults.Inflammasome-independent role of the apoptosis-associated speck-like protein containing CARD (ASC) in the adjuvant effect of MF59.Cell mediated immune responses following revaccination with an influenza A/H5N1 vaccine Impact of Adjuvants on the Immunogenicity and Efficacy of Split-Virion H7N9 Vaccine in Ferrets.Smart adjuvants.New adjuvants: EU regulatory developments.Adjuvanted H5N1 vaccine induces early CD4+ T cell response that predicts long-term persistence of protective antibody levels.Recombinant vesicular stomatitis virus expressing influenza nucleoprotein induces CD8 T-cell responses that enhance antibody-mediated protection after lethal challenge with influenza virus.Safety and immunogenicity of a subvirion inactivated influenza A/H5N1 vaccine with or without aluminum hydroxide among healthy elderly adults.Virus-like particle vaccines and adjuvants: the HPV paradigm.The ABC of clinical and experimental adjuvants--a brief overview.Preclinical evaluation of the safety and pathogenicity of a live attenuated recombinant influenza A/H7N9 seed strain and corresponding MF59-adjuvanted split vaccine.Cancer vaccine adjuvants--recent clinical progress and future perspectives.Effects of adjuvants on the safety and immunogenicity of an avian influenza H5N1 vaccine in adults.Impact of preexisting memory to seasonal A/H1N1 influenza virus on the immune response following vaccination against avian A/H5N1 virus.Development of a stable liquid formulation of live attenuated influenza vaccine.Adenovirus vector-based multi-epitope vaccine provides partial protection against H5, H7, and H9 avian influenza viruses.

P2860

Q21245319-72A5704F-73F9-4EA8-B1A2-996B814A7531 Q28536886-7BDDFEAA-4F49-4FE0-9F6E-A086041CD186 Q30210342-81E3EFFD-3319-4568-8F9C-6A077E969A9D Q30362332-1EF14312-0CDB-4323-9F41-EFC19473BBED Q30368247-E0EB7BC9-5750-4B93-B24A-D8CA9E2817A3 Q30372195-74C561AB-C3E1-4803-8568-84F68DE43643 Q30374764-317CE3AF-E380-4497-B7BE-CFC30D60FE95 Q30374887-814E0A33-C430-4F31-8F61-90CAEF91AEE5 Q30375972-4D14CB38-3AF7-4FEC-9069-62EC563B1612 Q30375975-90DB925F-174B-4792-AF98-245C36E522A7 Q30377214-270343C9-C4F3-4331-971F-CE6B88A19B01 Q30377220-84F23236-1249-4349-A972-25E9401EB4E9 Q30390753-2DF63CC1-CDF6-4922-A04A-05309FF39FC5 Q30393616-BB17313B-D69D-47A0-9D08-2CDE6BCA3F51 Q30393980-968D5A55-DB4E-481E-9A37-EC200A1969FF Q30394545-377E8489-1F72-4FFC-A823-3F245BF87797 Q30395094-DD90609B-D027-4B22-A2D2-5404B40DCF4A Q30406344-F361302E-5C53-44E5-AF67-C2578AE5D568 Q30424161-6C8729A8-933F-4BF7-9419-F61FBF98FDBD Q30424758-9FA679F2-7223-45BD-8602-E2DCF48DFE0C Q30426771-827BCFC5-C7F3-4CD9-8B3F-96A41729F919 Q34198807-46F45CF1-A9AB-43CB-9FEA-25C99027D681 Q34289880-D918C9D1-074E-47B9-AC00-5F26335235DD Q34498228-7772231F-114C-4DFB-B615-5122E0F9A587 Q34582628-79F21A96-A8D7-4B47-994F-8332BEBB88F2 Q35866636-98E8D1B5-4C7A-488B-85AB-13A15CA2E07E Q36139178-79D689E4-B279-4DBD-88A3-3E7DE0950577 Q36837149-284FA1A3-5DB0-4AF4-942D-A59637C421B8 Q36968305-F30FFB46-6CBA-4A52-9ED0-639C984B7C0B Q37106916-460A4248-B9F0-4F58-8ED6-AE731F50C5AC Q37156713-3861F516-E362-45BB-8973-655FDA8AACF1 Q37316012-BAB13E5D-254B-4E3E-BB7F-58AF10288D37 Q37608311-3A2DCEA7-DAD4-4A85-8EBB-D3F9B7E62F9B Q37628867-CEE87E46-EE3C-48F8-86C4-1FBABA8F924E Q37697111-2580385F-E752-406C-8BCF-37CF551775B5 Q38260496-EFBA414E-F4BE-4AB6-8D3F-5357BA03B6E4 Q38392346-D6BCE79E-EF04-4A90-9B92-0C0BC0286D6F Q39503548-D55C159E-134A-4BAE-A1FB-79109B19C824 Q40765131-BCA1F899-BC99-40E5-A66E-1C87EB6B6656 Q41918215-64FF19F5-B00F-48A2-9C23-F73897F777C3

P2860

Safety and immunogenicity of nonadjuvanted and MF59-adjuvanted influenza A/H9N2 vaccine preparations.

http://www.wikidata.org/entity/Q30357294

description

2006 nî lūn-bûn

@nan

2006 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

name

Safety and immunogenicity of n ...... a A/H9N2 vaccine preparations.

@ast

Safety and immunogenicity of n ...... a A/H9N2 vaccine preparations.

@en

type

label

Safety and immunogenicity of n ...... a A/H9N2 vaccine preparations.

@ast

Safety and immunogenicity of n ...... a A/H9N2 vaccine preparations.

@en

prefLabel

Safety and immunogenicity of n ...... a A/H9N2 vaccine preparations.

@ast

Safety and immunogenicity of n ...... a A/H9N2 vaccine preparations.

@en

P1433

Q30357294-EE6C004B-349C-4803-8A7C-80D404FD88FF

P1476

Q30357294-5D160D16-A71A-4A66-B667-AAE6A03CC9CA

P2093

Q30357294-012C0279-5B58-48BD-8A7F-33FF7AC8A217

Q30357294-1D66D517-202C-4E24-98BC-0FEE083B419D

Q30357294-3271425B-E973-4E4D-94B6-630672673649

Q30357294-BFAE0C94-650D-463E-965D-423EEF7D2F2D

Q30357294-E195C498-A6E8-409B-8100-B69A99ACB233

Q30357294-EF34848F-340C-4F99-931B-F4177893EBAF

P2860

Q30357294-25FFD2C9-6679-4ABE-A532-E0F6907FCF4D

Q30357294-3B0D1930-4843-4C10-A3A0-012015B84B36

Q30357294-661C8E94-0A33-4DD4-9DE2-687BAB236B5D

Q30357294-67F4E046-0F6F-4EF5-9676-2CE9415726F9

Q30357294-680CC5DE-C0F3-4628-AE7F-B05672EF8701

Q30357294-6B8995DF-9A20-457A-98E7-7D2138BF94F7

Q30357294-8DFEF3F8-1022-4163-9412-CA353B80CF07

Q30357294-AF227156-A7D0-48CE-8B4F-84EC726A2696

Q30357294-B96DAAE2-72B9-431C-B1FA-3149983CBC5F

Q30357294-C2471C33-A014-4AAD-BDAE-CAE11C8356A1

P304

Q30357294-12DF65D4-1860-4C4D-83EE-D5B24087E797

P31

Q30357294-9B270F2D-BFEE-40E4-915A-365A8A5E9D5D

P356

Q30357294-B7E5B020-1C41-4B43-B3B1-49B35F769069

P407

Q30357294-BC891AF4-D8D0-4DE7-85CD-F3CE018B8854

P433

Q30357294-8E110188-4F0B-46FB-B8F7-E080827423E0

P478

Q30357294-32A2ADCA-5561-4453-AF35-F59C98BB3B49

P50

Q30357294-1F6AAD12-0DB3-4252-A04B-AC4A133339B0

Q30357294-6FB00B31-1266-48C9-BB08-E8F78EA8A9B7

Q30357294-F2D9035B-FC56-44A6-9456-B90F5A7E0A01

P577

Q30357294-F9DA3FC8-44F1-4249-BD32-B039BE685DDD

P5875

Q30357294-FF6A4FF2-EED7-4FDA-B9F8-E5A7771C6AF8

P698

Q30357294-992F4927-AA0A-4F5F-B349-3909372F3E79

P356

P1433

Clinical Infectious Diseases

P1476

Safety and immunogenicity of n ...... a A/H9N2 vaccine preparations.

@en

P2093

Dewei She

http://www.w3.org/2001/XMLSchema#string

Hana El Sahly

http://www.w3.org/2001/XMLSchema#string

Justine Pompey

http://www.w3.org/2001/XMLSchema#string

Robert B Couch

http://www.w3.org/2001/XMLSchema#string

Shital M Patel

http://www.w3.org/2001/XMLSchema#string

Thomas R Cate

http://www.w3.org/2001/XMLSchema#string

P2860

Transmission of H7N7 avian influenza A virus to human beings during a large outbreak in commercial poultry farms in the Netherlands.

Pandemic preparedness: lessons learnt from H2N2 and H9N2 candidate vaccines.

Immunity to influenza A H9N2 viruses induced by infection and vaccination.

Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza.

Continuing evolution of H9N2 influenza viruses in Southeastern China.

Confronting the avian influenza threat: vaccine development for a potential pandemic.

Vaccination strategies for an influenza pandemic.

Cross-reactivity to highly pathogenic avian influenza H5N1 viruses after vaccination with nonadjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a potential priming strategy.

Human infection with an avian H9N2 influenza A virus in Hong Kong in 2003.

Avian influenza A (H5N1) in 10 patients in Vietnam.

P304

1135-1142

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1086/508174

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

43

http://www.w3.org/2001/XMLSchema#string

P50

Jacqueline M. Katz

P577

2006-09-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6766221

http://www.w3.org/2001/XMLSchema#string

P698

17029131

http://www.w3.org/2001/XMLSchema#string